Primaquine Phosphate has 15 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Primaquine, Quinacrine, Ergot-Type Oxytocic Drugs. Patients taking Primaquine Phosphate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 15
- Contraindicated
- 2
- Major
- 5
- Moderate
- 7
Contraindicated (2)
- Primaquine Phosphate + Primaquine— Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline.
- Primaquine Phosphate + Quinacrine— Concurrent use of quinacrine and primaquine phosphate is contraindicated due to increased toxicity.
Major (5)
- Primaquine Phosphate + Ergot-Type Oxytocic Drugs— As CYP3A4 substrates with minimal concentration changes that may lead to serious adverse reactions, concomitant use warr…
- Primaquine Phosphate + Hemolytic Agents— Concurrent administration of hemolytic agents with primaquine should be avoided; if necessary, close blood monitoring is…
- Primaquine Phosphate + Mao Inhibitors— Concomitant use in patients with reduced or absent CYP2D6 activity may increase primaquine exposure and risk of adverse …
- Primaquine Phosphate + Methemoglobinemia-Inducing Drugs— Concurrent administration of methemoglobinemia-inducing drugs with primaquine should be avoided; if necessary, close blo…
- Primaquine Phosphate + Rivaroxaban— As a CYP3A4 substrate with minimal concentration changes that may lead to serious adverse reactions, concomitant use war…
Moderate (7)
- Primaquine Phosphate + Alosetron— Primaquine may inhibit CYP1A2 and increase alosetron exposure; increased monitoring for adverse reactions is recommended…
- Primaquine Phosphate + Dabigatran— Primaquine may inhibit P-gp, potentially increasing dabigatran concentrations. Monitor for adverse reactions.
- Primaquine Phosphate + Digoxin— Primaquine may inhibit P-gp, potentially increasing digoxin concentrations. Monitor for adverse reactions.
- Primaquine Phosphate + Drugs That Prolong The Qt Interval— Caution is advised when primaquine is used concomitantly with other drugs that prolong the QT interval due to potential …
- Primaquine Phosphate + Duloxetine— Primaquine may inhibit CYP1A2 and increase duloxetine exposure; increased monitoring for adverse reactions is recommende…
- Primaquine Phosphate + Theophylline— Primaquine may inhibit CYP1A2 and increase theophylline exposure; increased monitoring for adverse reactions is recommen…
- Primaquine Phosphate + Tizanidine— Primaquine may inhibit CYP1A2 and increase tizanidine exposure; increased monitoring for adverse reactions is recommende…